Christin Lund-Andersen

  • Researcher; PhD
  • +47 22 78 17 61

Peritoneal metastasis (PM) is characterized by the presence of widespread tumor lesions on the peritoneal surfaces, and is a major cause of cancer death in abdominal malignancies. The peritoneum is the second most common site for metastatic colorectal cancer (CRC) after liver, and is implicated in at least 25-30% of recurrences. Patients with PM-CRC have a poor prognosis (median survival of 30 months), and are more resistant to chemotherapy compared to other metastatic sites such as liver and lung. PM originating from appendiceal tumors (pseudomyxoma peritonei, PMP), on the other hand, has a better prognosis, where current treatment may cure up to 50% of the patients. PMP is a rare disease characterized by abundant mucinous tumor tissue in the peritoneal cavity that eventually, if untreated, will compress and destroy the inner organs. PM is treated with cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPEC) to kill the remaining tumor cells. The treatment is quite demanding with risk of complications, and the outcome is highly variable. Thus, finding biomarkers and new therapeutic targets is needed to facilitate treatment selection and discover new possible treatment options for these patients.

To approach this aim, we are performing multilevel molecular analysis on PM-CRC and PMP patient samples, harvested during surgery at the Norwegian Radium Hospital. DNA/RNA, extracted from blood and tumor samples, are subjected to next-generation sequencing, and through bioinformatics analysis (which is my main focus) we retrieve knowledge of the mutation profiles, copy number variations, gene expression and fusion genes common for these diseases. Associating these data with clinical characteristics will give us important knowledge for improving patient care (fig1).

 

Publications 2022

Høye E, Dagenborg VJ, Torgunrud A, Lund-Andersen C, Fretland ÅA, Lorenz S, Edwin B, Hovig E, Fromm B, Inderberg EM, Greiff V, Ree AH, Flatmark K (2022)
T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
Gigascience, 12
DOI 10.1093/gigascience/giad032, PubMed 37161965

Høye E, Fromm B, Böttger PHM, Domanska D, Torgunrud A, Lund-Andersen C, Abrahamsen TW, Fretland ÅA, Dagenborg VJ, Lorenz S, Edwin B, Hovig E, Flatmark K (2022)
A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer
NAR Cancer, 4 (1), zcab051
DOI 10.1093/narcan/zcab051, PubMed 35047825

Publications 2021

Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
J Immunother Cancer, 9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663

Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K (2021)
Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
J Gastrointest Oncol, 12 (Suppl 1), S191-S203
DOI 10.21037/jgo-20-136, PubMed 33968437

Pavlović M, Scheffer L, Motwani K, Kanduri C, Kompova R, Vazov N, Waagan K, Bernal FLM, Costa AA, Corrie B, Akbar R, Al Hajj GS, Balaban G, Brusko TM, Chernigovskaya M, Christley S, Cowell LG, Frank R, Grytten I, Gundersen S, Haff IH, Hovig E, Hsieh PH, Klambauer G, Kuijjer ML et al. (2021)
The immuneML ecosystem for machine learning analysis of adaptive immune receptor repertoires
Nat Mach Intell, 3 (11), 936-944
DOI 10.1038/s42256-021-00413-z, PubMed 37396030

Publications 2020

Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
Transl Oncol, 13 (8), 100793
DOI 10.1016/j.tranon.2020.100793, PubMed 32447231

Publications 2019

Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K (2019)
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
Cold Spring Harb Mol Case Stud, 5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609

Publications 2017

Domanska D, Vodák D, Lund-Andersen C, Salvatore S, Hovig E, Sandve GK (2017)
The rainfall plot: its motivation, characteristics and pitfalls
BMC Bioinformatics, 18 (1), 264
DOI 10.1186/s12859-017-1679-8, PubMed 28521741

Simovski B, Vodák D, Gundersen S, Domanska D, Azab A, Holden L, Holden M, Grytten I, Rand K, Drabløs F, Johansen M, Mora A, Lund-Andersen C, Fromm B, Eskeland R, Gabrielsen OS, Ferkingstad E, Nakken S, Bengtsen M, Nederbragt AJ, Thorarensen HS, Akse JA, Glad I, Hovig E, Sandve GK (2017)
GSuite HyperBrowser: integrative analysis of dataset collections across the genome and epigenome
Gigascience, 6 (7), 1-12
DOI 10.1093/gigascience/gix032, PubMed 28459977

Publications 2016

Hasvold G, Lund-Andersen C, Lando M, Patzke S, Hauge S, Suo Z, Lyng H, Syljuåsen RG (2016)
Hypoxia-induced alterations of G2 checkpoint regulators
Mol Oncol, 10 (5), 764-73
DOI 10.1016/j.molonc.2015.12.015, PubMed 26791779

Publications 2014

Lund-Andersen C, Patzke S, Nähse-Kumpf V, Syljuåsen RG (2014)
PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule
Radiother Oncol, 110 (2), 355-61
DOI 10.1016/j.radonc.2013.12.014, PubMed 24502970

Publications 2011

Menzel T, Nähse-Kumpf V, Kousholt AN, Klein DK, Lund-Andersen C, Lees M, Johansen JV, Syljuåsen RG, Sørensen CS (2011)
A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance
EMBO Rep, 12 (7), 705-12
DOI 10.1038/embor.2011.99, PubMed 21637299

Tkacz-Stachowska K, Lund-Andersen C, Velissarou A, Myklebust JH, Stokke T, Syljuåsen RG (2011)
The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells
Radiother Oncol, 101 (1), 24-7
DOI 10.1016/j.radonc.2011.05.060, PubMed 21722983

Page visits: 6558
Scroll to top